Leslie Dakin

Pfizer (United States) — United States

Medicine · Health Sciences

7h-index458citations12works5.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal Diseases and Glomerulopathies(6), Coagulation, Bradykinin, Polyphosphates, and Angioedema(3), Immune Response and Inflammation(2), Immune Cell Function and Interaction(2), interferon and immune responses(2)

Publications12 total

Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca2+ dependent allosteric binding site
Nature Communications·2025· 8 citedOpen Access
Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease
Nature Communications·2025· 16 citedOpen Access
Small Molecule Inhibition of APOL1 Channel Activity Protects Podocytes from Mitochondrial Dysfunction, Cell Death, and Barrier Disruption Induced by APOL1 Risk Variants
Journal of the American Society of Nephrology·2024
Small Molecule APOL1 Channel Inhibitor Reduces Proteinuria, Rescues Podocyte Injury, and Reverses eGFR Decline in an APOL1-Mediated Kidney Disease Mouse Model
Journal of the American Society of Nephrology·2024
Small Molecule APOL1 Inhibitors as a Precision Medicine Approach for APOL1-mediated Kidney Disease
2024· 2 citedOpen Access
APOL1 Inhibitors Reverse Established Proteinuria in an APOL1-Mediated Kidney Disease Mouse Model
Journal of the American Society of Nephrology·2022
Small Molecule APOL1 Inhibitors Block APOL1 Pore Function and Reduce Proteinuria in an APOL1-Mediated Kidney Disease Mouse Model
Journal of the American Society of Nephrology·2021· 3 cited
The catalytic mechanism of cyclic GMP‐AMP synthase (cGAS) and implications for innate immunity and inhibition
Protein Science·2017· 65 citedOpen Access
Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay
PLoS ONE·2017· 157 citedOpen Access
Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors
Journal of Medicinal Chemistry·2016· 36 citedOpen Access
Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists
Scientific Reports·2016· 60 citedOpen Access
Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)
ACS Medicinal Chemistry Letters·2016· 111 citedOpen Access

Frequent Co-authors

Timothy J. Senter(5), Brinley F. Furey(5), Brandon Zimmerman(5), Fabien Vincent(4), A H Fortier(4), Evanthia Nanou(4), Angelo Blasio(4), Kelly Sullivan(4), Shyamesh Kumar(4), Jennifer Proctor(4), J. Perry Hall(3), Suman Shanker(3), John I. Trujillo(3), Mark E. Bunnage(3), Suganthini Nanthakumar(3), Gizelle M. McCarthy(3), Prachi D. Matsye(3), Kevin Daniel(3), Franklin Bright(3), Amy Brault(2)